The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration

Biomaterials

Volumn 33, Issue 28, 2012, Pages 6709-6720

  Lee, Jongman ^a   Yoo, James J ^a   Atala, Anthony ^a   Lee, Sang Jin ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Bioactivity; Cellular infiltration; Heparin; Protein delivery; Scaffold; Vascular tissue engineering

Indexed keywords

BURST RELEASE; CAPROLACTONE; CELLULAR INFILTRATION; CELLULAR INTERACTION; CONTROLLED RELEASE; ELECTROSPUNS; HEPARIN; IN-VITRO; PDGF BB'S; PHYSICAL ADSORPTION; PROTEIN DELIVERY; REACTIVE SURFACES; RELEASE PROFILES; SMOOTH MUSCLE CELLS; SUSTAINED RELEASE; VASCULAR TISSUE ENGINEERING;

ADSORPTION; BIOACTIVITY; ELECTROSTATIC SEPARATORS; MOLECULES; POLYSACCHARIDES; SCAFFOLDS;

SCAFFOLDS (BIOLOGY);

GELATIN; HEPARIN; PLATELET DERIVED GROWTH FACTOR BB;

ARTICLE; CELL INTERACTION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; ELECTROSTIMULATION; HUMAN; HUMAN CELL; IMMOBILIZATION; IN VITRO STUDY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANALYSIS OF VARIANCE; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; GELATIN; HEPARIN; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MYOCYTES, SMOOTH MUSCLE; POLYESTERS; PROTO-ONCOGENE PROTEINS C-SIS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84864006009     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.017     Document Type: Article

References (40)

1. Sill T.J., von Recum H.A. Electrospinning: applications in drug delivery and tissue engineering. Biomaterials 2008, 29(13):1989-2006.
2. Ju Y.M., Choi J.S., Atala A., Yoo J.J., Lee S.J. Bilayered scaffold for engineering cellularized blood vessels. Biomaterials 2010, 31(15):4313-4321.
3. Lee S.J., Liu J., Oh S.H., Soker S., Atala A., Yoo J.J. Development of a composite vascular scaffolding system that withstands physiological vascular conditions. Biomaterials 2008, 29(19):2891-2898.
4. Lee S.J., Yoo J.J., Lim G.J., Atala A., Stitzel J. In vitro evaluation of electrospun nanofiber scaffolds for vascular graft application. J Biomed Mater Res A 2007, 83(4):999-1008.
5. Burger C., Chu B. Functional nanofibrous scaffolds for bone reconstruction. Colloids Surf B Biointerfaces 2007, 56(1-2):134-141.
6. Szentivanyi A., Chakradeo T., Zernetsch H., Glasmacher B. Electrospun cellular microenvironments: understanding controlled release and scaffold structure. Adv Drug Deliv Rev 2011, 63(4-5):209-220.
7. Nie H., Ho M.L., Wang C.K., Wang C.H., Fu Y.C. BMP-2 plasmid loaded PLGA/HAp composite scaffolds for treatment of bone defects in nude mice. Biomaterials 2009, 30(5):892-901.
8. Chakraborty S., Liao I.C., Adler A., Leong K.W. Electrohydrodynamics: a facile technique to fabricate drug delivery systems. Adv Drug Deliv Rev 2009, 61(12):1043-1054.
9. Yang Y., Li X., Qi M., Zhou S., Weng J. Release pattern and structural integrity of lysozyme encapsulated in core-sheath structured poly(dl-lactide) ultrafine fibers prepared by emulsion electrospinning. Eur J Pharm Biopharm 2008, 69(1):106-116.
10. Huang X., Brazel C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 2001, 73(2-3):121-136.
11. Lee J., Yoo J.J., Atala A., Lee S.J. Controlled heparin conjugation on electrospun poly(ε-caprolactone)/gelatin fibers for morphology-dependent protein delivery and enhanced cellular affinity. Acta Biomater 2012, 8(7):2549-2558.
12. Guan R., Sun X.L., Hou S., Wu P., Chaikof E.L. A glycopolymer chaperone for fibroblast growth factor-2. Bioconjug Chem 2004, 15(1):145-151.
13. Lyon M., Rushton G., Gallagher J.T. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem 1997, 272(29):18000-18006.
14. Sun B., Chen B., Zhao Y., Sun W., Chen K., Zhang J., et al. Crosslinking heparin to collagen scaffolds for the delivery of human platelet-derived growth factor. J Biomed Mater Res B Appl Biomater 2009, 91(1):366-372.
15. Nam J., Huang Y., Agarwal S., Lannutti J. Improved cellular infiltration in electrospun fiber via engineered porosity. Tissue Eng 2007, 13(9):2249-2257.
16. Baker B.M., Gee A.O., Metter R.B., Nathan A.S., Marklein R.A., Burdick J.A., et al. The potential to improve cell infiltration in composite fiber-aligned electrospun scaffolds by the selective removal of sacrificial fibers. Biomaterials 2008, 29(15):2348-2358.
17. Welsh C.J., Schmeichel K., McBride K. Platelet-derived growth factor activates phospholipase D and chemotactic responses in vascular smooth muscle cells. In Vitro Cell Dev Biol 1991, 27A(5):425-431.
18. Mangrulkar R.S., Ono M., Ishikawa M., Takashima S., Klagsbrun M., Nowak R.A. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium. Biol Reprod 1995, 53(3):636-646.
19. Gospodarowicz D., Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986, 128(3):475-484.
20. Ho Y.C., Mi F.L., Sung H.W., Kuo P.L. Heparin-functionalized chitosan-alginate scaffolds for controlled release of growth factor. Int J Pharm 2009, 376(1-2):69-75.
21. Nillesen S.T., Geutjes P.J., Wismans R., Schalkwijk J., Daamen W.F., van Kuppevelt T.H. Increased angiogenesis and blood vessel maturation in acellular collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials 2007, 28(6):1123-1131.
22. Pieper J.S., Hafmans T., van Wachem P.B., van Luyn M.J., Brouwer L.A., Veerkamp J.H., et al. Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res 2002, 62(2):185-194.
23. Yoon J.J., Chung H.J., Lee H.J., Park T.G. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res A 2006, 79(4):934-942.
24. Sakiyama-Elbert S.E., Das R., Gelberman R.H., Harwood F., Amiel D., Thomopoulos S. Controlled-release kinetics and biologic activity of platelet-derived growth factor-BB for use in flexor tendon repair. J Hand Surg Am 2008, 33(9):1548-1557.
25. Sommer A., Rifkin D.B. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989, 138(1):215-220.
26. Bowen-Pope D.F., Malpass T.W., Foster D.M., Ross R. Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood 1984, 64(2):458-469.
27. Yao C., Roderfeld M., Rath T., Roeb E., Bernhagen J., Steffens G. The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. Biomaterials 2006, 27(8):1608-1616.
28. Shen H., Hu X., Yang F., Bei J., Wang S. Cell affinity for bFGF immobilized heparin-containing poly(lactide-co-glycolide) scaffolds. Biomaterials 2011, 32(13):3404-3412.
29. Okuda T., Tominaga K., Kidoaki S. Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. J Control Release 2010, 143(2):258-264.
30. Prestrelski S.J., Fox G.M., Arakawa T. Binding of heparin to basic fibroblast growth factor induces a conformational change. Arch Biochem Biophys 1992, 293(2):314-319.
31. Walker A., Turnbull J.E., Gallagher J.T. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 1994, 269(2):931-935.
32. Clowes A.W., Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265(5595):625-626.
33. Hoover R.L., Rosenberg R., Haering W., Karnovsky M.J. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II. In vitro studies. Circ Res 1980, 47(4):578-583.
34. Castellot J.J., Wong K., Herman B., Hoover R.L., Albertini D.F., Wright T.C., et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985, 124(1):13-20.
35. Park Y.J., Lee Y.M., Lee J.Y., Seol Y.J., Chung C.P., Lee S.J. Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration. J Control Release 2000, 67(2-3):385-394.
36. Lee J., Choi W.I., Tae G., Kim Y.H., Kang S.S., Kim S.E., et al. Enhanced regeneration of the ligament-bone interface using a poly(l-lactide-co-epsilon-caprolactone) scaffold with local delivery of cells/BMP-2 using a heparin-based hydrogel. Acta Biomater 2011, 7(1):244-257.
37. Sjolund M., Hedin U., Sejersen T., Heldin C.H., Thyberg J. Arterial smooth muscle cells express platelet-derived growth factor (PDGF) A chain mRNA, secrete a PDGF-like mitogen, and bind exogenous PDGF in a phenotype- and growth state-dependent manner. J Cell Biol 1988, 106(2):403-413.
38. Balguid A., Mol A., van Marion M.H., Bank R.A., Bouten C.V., Baaijens F.P. Tailoring fiber diameter in electrospun poly(epsilon-caprolactone) scaffolds for optimal cellular infiltration in cardiovascular tissue engineering. Tissue Eng Part A 2009, 15(2):437-444.
39. Eichhorn S.J., Sampson W.W. Statistical geometry of pores and statistics of porous nanofibrous assemblies. J R Soc Interface 2005, 2(4):309-318.
40. Pham Q.P., Sharma U., Mikos A.G. Electrospun poly(epsilon-caprolactone) microfiber and multilayer nanofiber/microfiber scaffolds: characterization of scaffolds and measurement of cellular infiltration. Biomacromolecules 2006, 7(10):2796-2805.